Skip to content

Clinical Efficacy Study of Traditional Chinese Medicine Compound Zican Ointment in the Treatment of Diabetic Foot Ulcers

Clinical Efficacy Study of Traditional Chinese Medicine Compound Zican Ointment in the Treatment of Diabetic Foot Ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000497
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcers

Interventions

Control Group: Basic treatment
Intervention Group:Basic treatment combined with traditional Chinese medicine compound Zican Ointment

Sponsors

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Conform to the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of diabetes Foot: 1) Have a history of diabetes; 2) Symptoms of malnutrition such as ulcers and gangrene on the feet; 3) Lower limb vascular disease associated with diabetes; 4) Combined with diabetes peripheral neuropathy; 5) Wagner grading 1-3 levels; (2) The course of diabetes is more than one year and the glycosylated hemoglobin is less than 8%; (3) Age range of 30 to 80 years old; (4) The patient signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with end-stage diabetes nephropathy and diabetes ketoacidosis; (2) Patients with combined ulcer malignancy and severe infection in the extra foot area; (3) The patient's condition is critical and requires amputation; (4) With other malignant tumors; (5) Patients with severe heart brain liver kidney digestive tract and hematological diseases; (6) Individuals with mental or neurological disorders who are unable to take medication on time or who abuse drugs and other substances; (7) Screening participants who have participated in any other clinical trials (enrolled and have used the investigational drug) within the past 3 months; (8) Pregnant lactating women and those planning to conceive in the near future; (9) Known or suspected allergy to the test drug; (10) Researchers believe that other reasons are not suitable for clinical trial participants.

Design outcomes

Primary

MeasureTime frame
Ulcer area of diabetes foot;Clinical efficiency;

Secondary

MeasureTime frame
Basic fibroblast growth factor;serum amyloid A;Traditional Chinese Medicine Symptom Score;Serum hs-CRP;Vascular endothelial growth factor;

Countries

China

Contacts

Public ContactQingyan Ye

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

yeqingyan11@163.com15921188681

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026